CF
AVIR icon

Corebridge Financial’s Atea Pharmaceuticals AVIR Stock Holding History

Corebridge Financial’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,802
Closed -$113K – 270
2025
Q1 		$113K Sell
37,802
-561
-1% -$1.75K ﹤0.01% 2378
2024
Q4 		$129K Sell
38,363
-2,896
-7% -$9.62K ﹤0.01% 2433
2024
Q3 		$138K Sell
41,259
-254
-0.6% -$921 ﹤0.01% 2431
2024
Q2 		$137K Buy
+41,513
New +$155K ﹤0.01% 2424

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corebridge Financial's AVIR Position: Q2 2025 in Review

Corebridge Financial sold out of Atea Pharmaceuticals (AVIR) in Q2 2025, closing a stake of 37,802 shares — an estimated $113K sold.

Corebridge Financial first reported a position in AVIR in Q2 2024 and held it in 4 quarters. The position peaked at $138K in Q3 2024. 106 funds tracked by Wall St. Rank hold AVIR as of Q2 2025.

  • Corebridge Financial reported no remaining Atea Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 37,802 Atea Pharmaceuticals shares in Q2 2025, an estimated $113K.
  • Corebridge Financial first reported a position in Atea Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Atea Pharmaceuticals position peaked at $138K in Q3 2024.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.